Fulminant myocarditis with complete atrioventricular block after mRNA COVID-19 vaccination: A case report
- PMID: 36779079
- PMCID: PMC9906563
- DOI: 10.1016/j.jccase.2023.01.004
Fulminant myocarditis with complete atrioventricular block after mRNA COVID-19 vaccination: A case report
Abstract
A 71-year-old man was transferred urgently to our hospital after collapsing near his home post the first shot of the BNT162b2 coronavirus disease 2019 vaccine (Pfizer-BioNTech, Comirnaty®). Immediately after arrival at our hospital, cardiac arrest due to complete atrioventricular block with no ventricular escaped beats was observed on electrocardiogram. Echocardiography showed preserved left ventricular ejection fraction, however, diffuse severe hypokinesia was revealed after 3 weeks, and he died 3 months after admission because of worsening heart failure. An autopsy examination revealed eosinophilic myocarditis or hypersensitivity myocarditis with extensive fibrosis and widespread myocardial dropout throughout the heart.
Learning objective: 1. Severe myocarditis occurs extremely rarely after mRNA coronavirus disease 2019 (COVID-19) vaccination. 2. Myocarditis after mRNA COVID-19 vaccination might cause complete atrioventricular block, followed by a course of decreased left ventricular ejection fraction. 3. Histologically, severe myocarditis after mRNA COVID-19 vaccination seems to present as fulminant necrotizing eosinophilic myocarditis or hypersensitivity myocarditis.
Keywords: BNT162b2; Complete atrioventricular block; Coronavirus disease 2019; Eosinophilic myocarditis; Hypersensitivity myocarditis; mRNA.
© 2023 Japanese College of Cardiology. Published by Elsevier Ltd.
Conflict of interest statement
None.
Figures



Similar articles
-
First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction.J Clin Immunol. 2022 Apr;42(3):441-447. doi: 10.1007/s10875-021-01187-0. Epub 2022 Jan 3. J Clin Immunol. 2022. PMID: 34978002 Free PMC article.
-
First Identified Case of Fatal Fulminant Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Necrotizing Hypersensitivity Reaction Different to Hypersensitivity or Drug-Induced Myocarditis.J Clin Immunol. 2022 May;42(4):736-737. doi: 10.1007/s10875-022-01228-2. Epub 2022 Feb 17. J Clin Immunol. 2022. PMID: 35178640 Free PMC article. No abstract available.
-
Ventricular tachycardia from myocarditis following COVID-19 vaccination with tozinameran (BNT162b2, Pfizer-BioNTech).Pacing Clin Electrophysiol. 2022 Sep;45(9):1097-1100. doi: 10.1111/pace.14486. Epub 2022 Apr 4. Pacing Clin Electrophysiol. 2022. PMID: 35306680 Free PMC article.
-
Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021.Heart Fail Rev. 2022 Nov;27(6):2033-2043. doi: 10.1007/s10741-022-10243-9. Epub 2022 Apr 22. Heart Fail Rev. 2022. PMID: 35449353 Free PMC article. Review.
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
Cited by
-
Commentary on: "Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination" by C. Schwab et al.Clin Res Cardiol. 2024 Feb;113(2):353-355. doi: 10.1007/s00392-023-02197-1. Epub 2023 Apr 25. Clin Res Cardiol. 2024. PMID: 37097464 Free PMC article. No abstract available.
-
Intra-atrial block after COVID-19 vaccination-induced fulminant myocarditis: a case report.Eur Heart J Case Rep. 2024 Oct 24;8(11):ytae580. doi: 10.1093/ehjcr/ytae580. eCollection 2024 Nov. Eur Heart J Case Rep. 2024. PMID: 39525510 Free PMC article.
References
-
- Oster M.E., Shay D.K., Su J.R., Gee J., Creech C.B., Broder K.R., Edwards K., Soslow J.H., Dendy J.M., Schlaudecker E., Lang S.M., Barnett E.D., Ruberg F.L., Smith M.J., Campbell M.J., et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327:331–340. - PMC - PubMed
-
- Ameratunga R., Woon S.T., Sheppard M.N., Garland J., Ondruschka B., Wong C.X., Stewart R.A.H., Tatley M., Stables S.R., Tse R.D. First identified case of fatal fulminant eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 vaccine (BNT162b2, Comirnaty): an extremely rare idiosyncratic hypersensitivity reaction. J Clin Immunol. 2022;42:441–447. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources